Search Results
Nov 11, 2025, 16:17 ET ABERDEEN INVESTMENTS U.S. CLOSED-END FUNDS ANNOUNCE DISTRIBUTION PAYMENT DETAILS
Aberdeen Investments U.S. Closed-End Funds (NYSE: ACP, AGD, AOD, ASGI, AWP, HQH, HQL, IFN, THQ, THW and NYSE American: FAX, FCO, IAF, VFL), announced today that the closed end funds in the chart directly below will pay the distributions indicated
More news about: Aberdeen Investments U.S. Closed End Funds
Nov 10, 2025, 08:30 ET 騰盛博藥在2025年AASLD大會上發佈ENSURE II期研究最新突破性數據，進一步強調BRII-179作為慢乙肝治癒性療法的潛力
-HBs 應答者 HBsAg 下降速度更快、幅度更大，這為縮短 PEG-IFN α治療週期提供了可能。 中國北京和美國北卡羅萊納州達勒姆市
More news about: 騰盛博藥生物科技有限公司
Sep 30, 2025, 17:10 ET ABERDEEN INVESTMENTS U.S. CLOSED-END FUNDS ANNOUNCE DISTRIBUTION PAYMENT DETAILS
Aberdeen Investments U.S. Closed-End Funds (NYSE: ASGI, HQH, HQL, IFN, THQ), (NYSE American: IAF) (the "Funds" or individually the "Fund"), today announced that the Funds paid the distributions noted in the table below
More news about: Aberdeen Investments U.S. Closed-End Funds
Sep 22, 2025, 00:15 ET First-in-Class Potential! FDA Clears IND Application for LBL-047, an Anti-BDCA2/TACI Bispecific Fusion Protein Developed by Leads Biolabs
their signaling. pDCs can produce large amounts of type I interferons (IFN-I, including IFN-α/β), activate T and B cells, and participate in autoimmune pathogenesis. BDCA2, a receptor uniquely expressed on pDCs, effectively inhibits IFN-I release and downstream effects upon activation. By targeting
More news about: Leads Biolabs
Sep 18, 2025, 20:33 ET AusperBio Completes Enrollment in Two Phase II Clinical Trials of AHB-137 for Chronic Hepatitis B
multicenter study to evaluate the efficacy and safety of AHB-137 Injection in combination with either a hepatitis B vaccine or pegylated interferon α-2b (Peg-IFN) in participants with HBeAg-negative CHB receiving nucleos(t)ide analogue (NA) therapy. The Phase II study AB-10-8008 (NCT06829329) is
More news about: AusperBio Therapeutics Inc.
Sep 17, 2025, 16:15 ET Dover Fueling Solutions and Bulloch Technologies Announce Certified Integration with Intevacon to Simplify Fleet Card Acceptance for Fuel Retailers
management, among other benefits. Leveraging the Intevacon Fuel Network (IFN), card issuers can provide access to more participating fuel sites for purchases beyond their local coverage area with built-in profit margins. Participating IFN Sites will enjoy daily settlement guaranteed by Intevacon. "This
More news about: Dover